


## VALUATION MULTIPLES

**Forward EV / EBITDA Multiples (monthly to 30/09/2020)** Source: FactSet Research Systems Inc.

Multiples in the Healthcare sector have increased over the period. At the end of September, the sector traded on a forward EV / EBITDA multiple of 10.5x, compared to the ASX200 on 9.4x.



**Average Values and Trading Multiples (values as at 26/10/2020)** Source: FactSet Research Systems Inc.

Subsector	Enterprise Value (\$ m)	EV/EBITDA FY2021	EV/EBIT FY2021	Price / Earnings FY2021
Aged Care	529	5.3x	9.5x	17.3x
Animal Health	130	9.1x	NA	11.9x
Biotech	144,358	19.1x	21.5x	27.2x
Hospitals & Clinics	45,976	9.6x	15.3x	20.4x
Medical Devices	2,040	10.8x	12.3x	20.0x
<b>Healthcare</b>	<b>194,009</b>	<b>10.4x</b>	<b>14.9x</b>	<b>19.7x</b>

Note: Multiples are based on the forward year of the unreported period, which for the majority of companies in the sector is FY2021. Difference in forward EV/EBITDA multiples between Figure and Table are representative of the timing difference between month-end result, and current day result.

Composition of companies in Sector Dashboards are updated every 6 months. Most recent update: October 2020.

## MERGER & ACQUISITION NEWS...

---



Value: AUD 14.1m

**Cryomed Australia**, an Australian distributor of aesthetic device and consumable products, has been acquired by **Ebos Group** for AUD 14.1m. The acquisition is expected to be completed by the end of October 2020 and it will be funded from existing facilities. It is expected to be immediately EPS accretive to EBOS shareholders.



Value: AUD 730m

**Infratil** [NZX:IFT, ASX:IFT] and **Morrison & Co** have agreed to acquire **QScan**, an Australian radiology business, for just over AUD 730m. The suitors agreed to a deal with QScan's owner **Quadrant Private Equity** over the weekend, following a quick round of exclusive negotiations.



MORRISON & CO

## UNDER THE MICROSCOPE...

---

- **Control Bionics**, an Australia-based healthcare technology business, is seeking to raise AUD 15m in an initial public offering. A successful listing would give the company a market capitalization of AUD 50m.
- **Haemokinesis**, an Australia-based blood analysis products business, is considering listing on the ASX in March.
- **Cabot Health**, a privately held Australian health supplements producer and health books publisher is keen to scale offshore and remains receptive to selling a majority stake.
- **Leef Independent Living Solutions**, a private Australian national supplier and retailer of assisted living products for the aged and disability care sectors, could consider acquisitions to support its core organic growth strategy.
- **I-Med Radiology** is looking for smaller bolt on acquisitions in Australia and is considering entering the UK and US markets. I-Med is owned by **Permira**, who acquired the business in 2018 for AUD 1.25bn.
- **HitIQ**, an Australia-based smart mouthguard business, is planning to list on the ASX in 2021 via an IPO.
- **Vaxxas**, an Australia-based biotechnology company, has secured a USD 22m investment from the US Government's Biomedical Advanced Research and Development Authority (BARDA).
- **ESN Cleer**, a private Australian developer of a first-to-market home-use saliva test to detect early risk of heart failure, is actively seeking commercialization capital.
- **TPG Capital** have secured an AUD 200m funding package to recapitalize **Novotech**, an Australia-based clinical research business.
- **Ramsay Health Care** is believed to be eyeing three mental healthcare assets in France, operated by **Inicea**.
- **Chimeric Therapeutics**, an Australian immuno-oncology CAR-T cell therapy developer, is evaluating a range of options for its next capital raise for further clinical developments.
- **Pacific Blue Health**, the Sydney-based marketer of the Elementelle Probiotics brand, is searching for partners to enter offshore markets, initially China, followed by the US and Europe.

## CONTACT DETAILS

If you are interested in specific information regarding mergers and acquisitions in the Healthcare sector, please contact David Hassum or Michael Kakanis.

Name	Position	Phone	Email
Sharon Doyle	Executive Chair	(07) 3218 9122	<a href="mailto:sdoyle@interfinancial.com.au">sdoyle@interfinancial.com.au</a>
Paul Keehan	Non-Executive Director	(07) 3218 9100	<a href="mailto:pkeehan@interfinancial.com.au">pkeehan@interfinancial.com.au</a>
Ted Marchant	Non-Executive Director	(07) 3218 9100	<a href="mailto:tmarchant@interfinancial.com.au">tmarchant@interfinancial.com.au</a>
Mark Steinhardt	Head of M&A	(07) 3218 9105	<a href="mailto:msteinhardt@interfinancial.com.au">msteinhardt@interfinancial.com.au</a>
Brad Shaw	Director – M&A	(07) 3218 9100	<a href="mailto:bshaw@interfinancial.com.au">bshaw@interfinancial.com.au</a>
Brent Wall	Director – M&A	(07) 3218 9102	<a href="mailto:bwall@interfinancial.com.au">bwall@interfinancial.com.au</a>
David Hassum	Director	(07) 3218 9108	<a href="mailto:dhassum@interfinancial.com.au">dhassum@interfinancial.com.au</a>
Andrew Wheeler	Director	(07) 3218 9107	<a href="mailto:awheeler@interfinancial.com.au">awheeler@interfinancial.com.au</a>
Michael Kakanis	Associate	(07) 3218 9106	<a href="mailto:mkakanis@interfinancial.com.au">mkakanis@interfinancial.com.au</a>
Lachlan O'Rourke	Analyst	(07) 3218 9104	<a href="mailto:lorourke@interfinancial.com.au">lorourke@interfinancial.com.au</a>

## DISCLAIMER

This information has been sourced from the ASX, Mergermarket.com and various other public information sources. Forecasts are consensus forecasts sourced from FactSet Research Systems Inc.

**Important Disclaimer** – This may affect your legal rights: Because this document has been prepared without consideration of any specific person's financial situation, particular needs and investment objectives, a financial services licensee or investment adviser should be consulted before any investment decision is made. While this document is based on information from sources which are considered reliable, InterFinancial, its directors, employees and consultants do not represent, warrant or guarantee, expressly or impliedly, that the information contained in this document is complete or accurate. Nor does InterFinancial accept any responsibility to inform you of any matter that subsequently comes to notice, which may affect any of the information contained in this document. This document is a private communication to clients and is not intended for public circulation or for the use of any third party, without the prior approval of InterFinancial. This report does not constitute advice to any person.

**Disclosure.** InterFinancial has no interest in any of the securities mentioned in this publication. However, its directors, executives or consultants may have an interest in some of the securities, directly or indirectly, which are mentioned.

*InterFinancial is a member of Clairfield International, an international corporate finance firm that provides advisory services in crossborder mergers and acquisitions. Clairfield is represented by over 400 people across 22 countries, closing over 100 transactions each year.*

<p><b>InterFinancial</b> Corporate Finance Limited ABN: 49 136 962 966 AFSL: 341675 Level 2, 201 Charlotte Street GPO Box 975 Brisbane Queensland 4001 (07) 3218 9100 admin@interfinancial.com.au www.interfinancial.com.au</p>	
---	---